Fundraising Fox
Immunitas Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 18 employees on LinkedIn · 12 known investors
Find your way into Immunitas Therapeutics
Sign up to see every warm intro you have to Immunitas Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunitas Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
Founders & leadership
Board
Investors · 12
How we know: Agent Capital's portfolio page · a partner's Signal profile · funding news · the VCSheet dataset · Not right? Tell us
How we know: DC Investment Partners's portfolio page · Not right? Tell us
How we know: Longwood Fund's portfolio page · board seat on SEC Form D · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Medical Excellence Capital's portfolio page · a partner's Signal profile · funding news · the VCSheet dataset · Not right? Tell us
How we know: Novartis Venture Fund's portfolio page · funding news · Not right? Tell us
How we know: Ono Venture Investment, Inc.'s portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
How we know: funding news · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$29.1M disclosed across 1 of 2 rounds · 2019–2021
- Undisclosed amountSeries ANov 2019Source ↗
▶$29.1MraisedAug 2021 · 21 investors · BiotechnologyRule 506(b)
- Laura BrassDirector
- Amanda WagnerExecutive Officer
- Kai WucherpfennigDirector
- Dan MatloffExecutive Officer
- Jiaping GuDirector
- Jeffrey GoldbergExecutive Officer, Director
- Juergen EckhardtDirector
- Christoph WestphalDirector
- Lucio IannoneDirector
- Offering amount
- $57.7M
- Amount sold
- $29.1M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Immunitas Therapeutics.
In the news
Frequently asked questions
- What does Immunitas Therapeutics do?
- Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
- Who are Immunitas Therapeutics's investors?
- Immunitas Therapeutics's investors include Agent Capital, DC Investment Partners, Lifelink, Longwood Fund, Medical Excellence Capital, Novartis Venture Fund, Ono Venture Investment, Inc., Solasta Ventures and 4 more.
- How much funding has Immunitas Therapeutics raised?
- Immunitas Therapeutics has disclosed $29.1M raised across 1 of its 2 known rounds.
- Where is Immunitas Therapeutics headquartered?
- Immunitas Therapeutics is headquartered in Waltham, US.